U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
“For people living with hemophilia, disease management can interfere with many aspects of their lives.
- “For people living with hemophilia, disease management can interfere with many aspects of their lives.
- A one-time infusion of BEQVEZ may allow eligible patients more time for the things they love,” said Kim Phelan, Chief Operating Officer, The Coalition for Hemophilia B.
- “We are excited to have BEQVEZ as a promising treatment option for eligible people living with hemophilia B.
- A Biologics License Application and European Marketing Authorization Application for marstacimab are currently under review with the FDA and EMA, respectively.